FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

Many people with COPD don’t notice the early symptoms. Here's how to spot subtle signs, get diagnosed early, and explore new ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Standard COPD treatment includes older medications ... Dupixent is an antibody designed to block the IL-3 and IL-4 pathways. The drug currently has approvals in seven indications, most recently ...

Not only are the neutrophils overstimulated, their pathways of activation and ... become more aware of their benefits in COPD. Corticosteroid treatment may be detrimental to the effectiveness ...

A robust treatment plan for COPD includes a combination of prescription medication, pulmonary therapies, and healthy lifestyle changes to help relieve symptoms and slow disease progression.

In 2019, COPD was responsible for ... all designed to act on specific molecular pathways and tailored to selected patient populations. Beyond drug treatments, several non-pharmacological ...

Most COPD treatments come as inhalers ... Tamping down the IL-13 pathway could also help regulate mucus production in the lungs. A pair of late-stage clinical trials showed Dupixent was effective ...

Companies are exploring alternative treatment pathways and have several novel classes of drugs for COPD in development (Table 1), including inhibitors of leukotriene B 4 receptors and chemokine ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials ...

A new way of treating serious asthma and chronic obstructive pulmonary disease (COPD) attacks could be a “game-changer” and is the first leap in treatment for 50 years, researchers say.